CAMBRIDGE, UK - Sareum Holdings plc (AIM: SAR), a biotechnology company specializing in the development of kinase inhibitors for treating autoimmune diseases and cancer, has announced its Annual General Meeting (AGM) is scheduled for 10:00 am on December 19, 2024, at 88 Wood Street, London. Shareholders are invited to attend the meeting in person or follow the proceedings online through the Investor Meet Company platform.
To attend the AGM physically, shareholders must register their intent via email or present the notice of the AGM at the venue. For online attendance, registration on the IMC platform is required. While online attendees will be able to view the AGM, they will not have the ability to vote during the meeting.
Sareum has encouraged shareholders to submit questions for the Board's Q&A session, which will take place after the formal proceedings. Questions can be sent through the IMC platform until the morning prior to the AGM, and during the meeting itself.
Voting will be accessible via the shareholder portal or by requesting a paper proxy form from Link Group. The company has emphasized that in order to vote, shareholders must utilize the portal or submit a proxy form.
The notice of the AGM and the annual report and accounts for the year ending June 30, 2024, will be distributed to shareholders who have requested hard copies and will also be available on the company's website.
This announcement is based on a press release statement from Sareum Holdings plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.